Clinical Trial Update: XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia [EARLY_Phase 1]

View source ↗

Summary

This early-phase 1 trial update covers XP-005, a personalized cancer vaccine used alone or in combination with toripalimab for preventing relapse after remissio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Toripalimab (Toripalimab)
• XP-005

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Acute Myeloid Leukemia | EARLY_Phase 1 | Status: RECRUITING